300 related articles for article (PubMed ID: 28895472)
41. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis.
Rižner TL; Penning TM
Pharmacol Res; 2020 Feb; 152():104446. PubMed ID: 31546014
[TBL] [Abstract][Full Text] [Related]
42. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system.
Park AL; Lin HK; Yang Q; Sing CW; Fan M; Mapstone TB; Gross NL; Gumerlock MK; Martin MD; Rabb CH; Fung KM
Int J Clin Exp Pathol; 2010 Mar; 3(8):743-54. PubMed ID: 21151387
[TBL] [Abstract][Full Text] [Related]
44. Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3.
Liu J; He P; Lin L; Zhao Y; Deng W; Ding H; Li Q; Wang Z
Steroids; 2019 Mar; 143():73-79. PubMed ID: 30639543
[TBL] [Abstract][Full Text] [Related]
45. Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Adeniji AO; Twenter BM; Byrns MC; Jin Y; Winkler JD; Penning TM
Bioorg Med Chem Lett; 2011 Mar; 21(5):1464-8. PubMed ID: 21277203
[TBL] [Abstract][Full Text] [Related]
46. Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Liu Y; He S; Chen Y; Liu Y; Feng F; Liu W; Guo Q; Zhao L; Sun H
J Med Chem; 2020 Oct; 63(20):11305-11329. PubMed ID: 32463235
[TBL] [Abstract][Full Text] [Related]
47. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer.
Liu Y; Chen Y; Jiang J; Chu X; Guo Q; Zhao L; Feng F; Liu W; Zhang X; He S; Yang P; Fang P; Sun H
Eur J Med Chem; 2023 Feb; 247():115013. PubMed ID: 36566714
[TBL] [Abstract][Full Text] [Related]
48. Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Biochem Pharmacol; 2018 Oct; 156():22-31. PubMed ID: 30077642
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Kikuchi A; Furutani T; Azami H; Watanabe K; Niimi T; Kamiyama Y; Kuromitsu S; Baskin-Bey E; Heeringa M; Ouatas T; Enjo K
Invest New Drugs; 2014 Oct; 32(5):860-70. PubMed ID: 24981575
[TBL] [Abstract][Full Text] [Related]
50. Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Loriot Y; Fizazi K; Jones RJ; Van den Brande J; Molife RL; Omlin A; James ND; Baskin-Bey E; Heeringa M; Baron B; Holtkamp GM; Ouatas T; De Bono JS
Invest New Drugs; 2014 Oct; 32(5):995-1004. PubMed ID: 24771350
[TBL] [Abstract][Full Text] [Related]
51. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.
Tian Y; Zhao L; Wang Y; Zhang H; Xu D; Zhao X; Li Y; Li J
Asian J Androl; 2016; 18(4):607-12. PubMed ID: 26698234
[TBL] [Abstract][Full Text] [Related]
52. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
[TBL] [Abstract][Full Text] [Related]
53. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
54. Steroid hormone transforming aldo-keto reductases and cancer.
Penning TM; Byrns MC
Ann N Y Acad Sci; 2009 Feb; 1155():33-42. PubMed ID: 19250190
[TBL] [Abstract][Full Text] [Related]
55. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
He S; Chu X; Wu Y; Jiang J; Fang P; Chen Y; Liu Y; Qiu Z; Xiao Y; Li Z; Pan D; Zhang Q; Xie H; Xing S; Feng F; Liu W; Guo Q; Zhao L; Yang P; Sun H
J Med Chem; 2023 Jul; 66(14):9537-9560. PubMed ID: 37409679
[TBL] [Abstract][Full Text] [Related]
56. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
57. Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors.
Zheng X; Jiang Z; Li X; Zhang C; Li Z; Wu Y; Wang X; Zhang C; Luo HB; Xu J; Wu D
Bioorg Med Chem; 2018 Dec; 26(22):5934-5943. PubMed ID: 30429100
[TBL] [Abstract][Full Text] [Related]
58. Insulin-Induced AKR1C3 Induces Fatty Acid Synthase in a Model of Human PCOS Adipocytes.
Paulukinas RD; Penning TM
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36799021
[TBL] [Abstract][Full Text] [Related]
59. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3).
Brozic P; Golob B; Gomboc N; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):233-5. PubMed ID: 16337332
[TBL] [Abstract][Full Text] [Related]
60. In silico study of novel alpha tocopheroids as effective inhibitors of aldo-keto reductase 1c3 (AKR1C3) enzyme.
Basu T; Upadhyay AK
J Biomol Struct Dyn; 2023 Aug; ():1-15. PubMed ID: 37534497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
